Organon and Philips team up to study drug effects at the molecular level
N.V. Organon, the human health care business unit of Akzo Nobel, and Royal Philips Electronics announced that they will join forces in the development of new drugs and therapies for mental disorders and cancer. With the help of biomarkers and Philips' advanced non-invasive medical imaging technology, it shall for example be possible to study the effects of psychiatric drugs in the brain at the molecular level.
Molecular imaging technologies are expected to speed up the development and approval of new drugs and therapies by measuring drug effects at the molecular level. In addition, these imaging technologies can be used to monitor the effect of the therapy and customize the treatment program accordingly. Such customized treatment programs could increase effectiveness and comfort, and ultimately accelerate and improve patient outcomes.
As part of the agreement, scientists from Organon will work at the Philips Life Sciences Facilities to identify, validate, and above all, exploit novel biomarkers. The Life Sciences Facilities, situated at the High Tech Campus in Eindhoven, is a multi-disciplinary research facility, which provides the necessary biological, chemical and technical infrastructure and expertise for research and development in the field of translational biomarkers and molecular medicine.
Other news from the department business & finance
